The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).
 
Ciara Conduit
Honoraria - AstraZeneca
 
Blossom Mak
No Relationships to Disclose
 
Wenjia Qu
No Relationships to Disclose
 
Theresa Yeung
No Relationships to Disclose
 
Mathias Bressel
No Relationships to Disclose
 
Thomas Cusick
No Relationships to Disclose
 
Haryana M. Dhillon
Honoraria - BMS (Inst)
Consulting or Advisory Role - Janssen Oncology (Inst)
 
Richard De Abreu Lourenço
Consulting or Advisory Role - Vifor Pharma (I)
 
Craig Underhill
Consulting or Advisory Role - AstraZeneca; Bayer; Merck Serono
Speakers' Bureau - AstraZeneca; IQvia
Research Funding - Akeso Biopharma (Inst); Arcus Biosciences (Inst); AtriCure (Inst); BeyondSpring Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); novotech (Inst)
 
Javier Torres
No Relationships to Disclose
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Florian Honeyball
Stock and Other Ownership Interests - ETFs reflecting the ASX 300
 
Anthony Linton
Honoraria - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Galderma (I)
 
Sanjeev Sewak
No Relationships to Disclose
 
Nguyen Minh Hieu Chau
No Relationships to Disclose
 
Ray Allen
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Susan J. Clark
No Relationships to Disclose
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen-Cilag; MSD Oncology; Pfizer
 
Kate Lynette Mahon
No Relationships to Disclose